Publications by authors named "Alan Jessiman"

Claim this Profile
D
Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.
Mark D Andrews, Kerry Af Forselles, Kevin Beaumont, Sébastien R G Galan, Paul A Glossop, Alan Jessiman

ACS Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.
Guy Rouquet, Dianna E Moore, Malcolm Spain, Daniel M Allwood, Claudio Battilocchio, Alan S Jessiman

ACS Med Chem Lett· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.
R Ian Storer, Paul E Brennan, Alan D Brown, Peter J Bungay, Kelly M Conlon, Alan S Jessiman

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.
Mark D Andrews, Paul V Fish, Julian Blagg, Tiffini K Brabham, Paul E Brennan, Alan S Jessiman

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.
Donald S Middleton, Mark Andrews, Paul Glossop, Geoffrey Gymer, David Hepworth, Alan Jessiman

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.
Donald S Middleton, Mark Andrews, Paul Glossop, Geoffrey Gymer, David Hepworth, Alan Jessiman

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal diversity construction via a branching synthetic strategy.
Emma E Wyatt, Suzanne Fergus, Warren R J D Galloway, Andreas Bender, David J Fox, Alan S Jessiman

Chem Commun (Camb)· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
Donald S Middleton, Mark Andrews, Paul Glossop, Geoffrey Gymer, Alan Jessiman

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
Donald S Middleton, Graham N Maw, Clare Challenger, Alan Jessiman, Patrick S Johnson

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total synthesis of spongistatin 1: a synthetic strategy exploiting its latent pseudo-symmetry.
Matthew Ball, Matthew J Gaunt, David F Hook, Alan S Jessiman, Shigeru Kawahara

Angew Chem Int Ed Engl· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of the C-1-C-28 ABCD unit of spongistatin 1.
Matthew J Gaunt, Alan S Jessiman, Paolo Orsini, Huw R Tanner, David F Hook

Org Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis